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Autism spectrum disorder (ASD) is a heterogeneous condition affecting an individual’s
ability to communicate and socialize and often presents with repetitive movements or
behaviors. It tends to be severe with less than 10% achieving independent living with
a marked variation in the progression of the condition. To date, the literature supports
a multifactorial model with the largest, most detailed twin study demonstrating strong
environmental contribution to the development of the condition. Here, we present a brief
review of the neurological, immunological, and autonomic abnormalities in ASD focusing
on the causative roles of environmental agents and abnormal gut microbiota. We present
a working hypothesis attempting to bring together the influence of environment on the
abnormal neurological, immunological, and neuroimmunological functions and we explain
in brief how such pathophysiology can lead to, and/or exacerbate ASD symptomatology.
At present, there is a lack of consistent findings relating to the neurobiology of autism.
Whilst we postulate such variable findings may reflect the marked heterogeneity in clini-
cal presentation and as such the variable findings may be of pathophysiological relevance,
more research into the neurobiology of autism is necessary before establishing a working
hypothesis. Both the literature review and hypothesis presented here explore possible neu-
robiological explanations with an emphasis of environmental etiologies and are presented
with this bias.
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INTRODUCTION
Autism spectrum disorder (ASD) is a neurodevelopmental dis-
order of unknown etiology. Recent evidence suggests a strong
environmental component (1) and persistent neuroinflammation
(2–5). Within the phenology of ASD and associated disorders,
the subjectivity involved in attributing an infant or toddler with
introversion (or being in one’s own world, autism) is fraught with
difficulty. The difficulty is not whether such behavioral abnormali-
ties represent a neurobiological illness – consensus is for an organic
brain disorder – the challenge stems from the wide-ranging possi-
bilities underlying the visible disease (6, 7). A secondary obstacle
to the adequate identification of disease process in ASD patients
pertains to scientific disparity. Research efforts have focused more
on the genetic aspects of ASD than on environmental factors over
the previous 15 years (8). Consequently, several important factors
have impinged upon progress for ASD sufferers and those at risk.
The fixation on genetics led to reprioritization by medical staff
and displacement of non-genetic scientific researchers. Many clin-
icians awaited the genetic answer and the promise of targeted,
scientifically originated treatment. Conveying the certainty of the
scientific consensus at the time, clinicians are now faced with the
same patients and a different, almost polar growing certainty: there
are likely to be prognostic factors one can mitigate (9, 10).
Previous twin studies suggested a predominant genetic compo-
nent; however, these studies were poorly designed and had weak
power (16, 17). A recent twin study published in July 2011 was
well-designed with a substantial statistical power. One hundred
ninety-four twin groups were studied and clinically evaluated prior
to statistical analysis. Probandwise concordance for monozygotic
twins was 77% (95% CI, 65–86%) for 45 male pairs and 50% (95%
CI, 16–84%) for 9 female pairs. Concordance rates for dizygotic
twins were 31% (95% CI, 16–46%) and 36% (95% CI, 11–60%)
for 45 male and 13 female pairs, respectively. The study con-
cluded: autism has substantial environmental factors, and indeed
the environmental factors were of more significance than genetic
factors (1).
There has been another compounding factor. Diagnostic label-
ing has changed substantially. Since its discovery in the late
1930s, autism has gradually become the diagnosis of choice. It
has replaced and superseded childhood schizophrenia and feeble-
mindedness and has encompassed within the spectrum, a host
of neurodevelopmental disorders [for review see Ref. (11)]. This
allowed a rational argument for the increase in prevalence, and as
such a tempering of the strict scientific critique required.
Recent advancements in ASD research has led to a surge in
research activity, in particular neuro-immune and environmental
factors. Here, we present a view of ASD related to neurological,
immunological, and neuroimmunological findings from the bias
of an environmental etiology standpoint. We briefly discuss the
pertinent literature concerning the frequently reported abnormal
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gut microflora composition in ASD patients. Finally, based on
the growing consensus in biological scientific evidence and clini-
cal experience, we present the variable insult model of ASD with
the aim of contributing further to a useful research direction for
those suffering from ASD and for those faced with managing the
condition.
EPIDEMIOLOGY
Autism spectrum disorder was first identified by Kanner in 1938
(12). Over the subsequent 10 years, Kanner discovered 50 further
cases (13). Kanner subsequently reviewed the first 11 patients at
30-year follow-up. Only one known patient achieved employment
(14). More recent evidence also suggests a high level of disability
in affected individuals, with 60–75% achieving poor or very poor
outcomes in adulthood (15).
Autism spectrum disorder case detection rates are now sub-
stantially higher – from 1 in 3000 reported in 1966 (including
both autism and psychosis) (16), 1 in 150 in 8-year-olds in 2007
[Centre for Disease Control (CDC), (17)], and in 2012 a rate of 1
in 88 [CDC, (18)]. In UK, Cohen et al. described a prevalence rate
of 1 in 64 (19).
MORBIDITY AND MORTALITY
Shavelle et al. investigated the mortality rate of ASD in over 13,000
patients between 1983 and 1997 (20) and found it to be more
than twice that of neurotypical peers. Standardized mortality
ratio (SMR) was estimated as 2.4. Certain causes carried signif-
icantly higher SMR (see Table 1). Similar mortality rates have
been reported in other studies (21, 22) with a consistent increased
mortality rate for ASD, and a substantially greater risk in female
ASD patients. Whilst mental retardation predicted risk of early
demise, those without mental retardation also had increased risk.
DISEASE PROGRESSION
There have been several studies evaluating diagnostic stability over
time. Turner et al. reassessed 2-year-olds diagnosed with ASD at
4.5 years of age (23) and found no change in their diagnosis of
ASD but did find that 20% of children worsened between 2 years
of age and 4.5 years of age and 20% improved. Within the para-
meters addressed, 60% remained relatively stable. No reason was
identified for the variation.
Levy et al. have recently reviewed the literature regarding long-
term outcome in ASD finding cognitive improvement in 20–55%,
cognitive stability in 20–70%, and cognitive loss in 10–15% (24).
No reasons were identified for why some ASD patients suffer a pro-
gressive illness and others make some recovery. ASDs as a group
carry a poorer prognosis than other developmental disorders in
almost all domains (24).
SUMMARY OF EPIDEMIOLOGICAL FINDINGS
Even though ASD is associated with high health, social, and finan-
cial impacts, investigative epidemiology has been limited. Perhaps
the premature acceptance of ASD as a genetic condition limited the
power of epidemiological science beyond that of detection of cases
[for review see Ref. (25)]. The Interagency Autism Coordinating
Committee (IACC) and Centers for Autism and Developmental
Disabilities Research and Epidemiology (CADDRE) Network are
Table 1 | Causes of death in ASD with moderate to severe retardation
or none to mild retardation (in brackets).
Cause of death Early childhood
SMR
(5–10 years)
Late childhood
SMR
(10–20 years)
Adulthood
SMR
(>20 years)
Drowning 90.6 (14.1) n/s n/s
Digestive n/s 40.8 5.9
Respiratory n/s 24.5 9.4
Cancer n/s 12.0 (3.8) 2.4 (1.6)
Nervous and sense n/s 6.4 (15.9) 4.1
Seizures n/s n/s 30.8 (33.1)
Cardiovascular n/s n/s 3.7 (2.2)
Adapted from Ref. (20). SMR, standardized mortality ratio; n/s, no significant
increase in SMR found in either group.
co-ordinating a large epidemiological study in the US: the study
to explore early development (SEED) (26). This is in keeping with
the responsibilities set out in the US through “The Combating
Autism Act 2006.”
IMMUNE ABNORMALITIES AND NEUROINFLAMMATION IN
ASD
Perhaps one of the most substantive studies in the last decade was
conducted at the John Hopkins Institute, and involved an analysis
of autopsy specimens and cerebrospinal fluid (CSF) samples from
affected individuals and controls (2). The results indicated a neu-
roinflammatory response, regardless of age (in patients between
5 and 46 years of age), involving excess microglial activation and
increased pro-inflammatory cytokine profiles. The study carries
high statistical significance [for review of study, see Ref. (27)]
and indicates an inflammatory state probably exists in the brains
of these patients. Similar findings were found in a more recent
autopsy study of microglia densities in fronto-insular and visual
cortices of patients with ASD versus controls, and found a sta-
tistically significant (p≤ 0.0002) increase in microglial density in
both regions (4). Other immune abnormalities have also been
found indicating an inflammatory state. Transforming growth fac-
tor beta 1 (TGF-β1) is reduced in ASD cohorts versus controls and
individuals with other developmental disorders and was found
to be inversely proportional to behavior outcomes (irritability,
lethargy, stereotypy, and hyperactivity) as well as with levels of
social adaptability (28).
Natural killer cells (NK cells) are abnormal in sub-groups of
ASD. NK cells respond to macrophage-derived cytokines and are
essential in tumor prevention and host anti-viral activity. Enstrom
et al. (29) found a significant reduction in NK cell cytotoxicity and
a 2.5-fold increase in KSP-37, an NK gene normally induced during
active viral infection. They concluded that ASD patients have acti-
vated but resting NK cells with increased levels of cytolytic proteins
and an altered response to stimulation with changes in gene expres-
sion (29). Supporting these findings, cancer mortality rates are
higher in ASD (20), and the only identified risk factor for mortal-
ity associated with the recent H1N1 outbreak was developmental
delay (30). Both of these findings suggest immune dysfunction in
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ASD, and either or both of these findings could be linked with the
NK cell abnormalities identified by Enstrom et al. (29).
There have been studies making correlations between mea-
sures of immune functions and cytokine profiles with behav-
ioral measures in ASD (Table 2). Significant correlations were
shown between certain behavioral indices and the chemokine’s,
macrophage chemoattractant MCP-1, macrophage inflamma-
tory protein (MIP)-1β, eotaxin, and “regulated upon activation
normal T-cell expressed and secreted” factor (RANTES) (31).
RANTES was associated with lethargy, stereotypy, and hyperactiv-
ity. Eotaxin was associated with hyperactivity, visual perception,
fine motor control, expressive language, communication and daily
living skills, and socialization. MCP-1 was associated with visual
perception. These associations, if proven to be functional, raise
many questions pertaining to the immune system’s connectivity to
the nervous system and involvement in neurobehavioral illnesses
(for summary of immunological findings relating to behavior in
ASD,see Table 2). Of importance here is the probability of immune
involvement in the core features of ASD. These findings also raise
the possibility of assessing behavioral changes in ASD through a
quantitative measure.
NEUROLOGICAL ABNORMALITIES IN ASD
With the exception of neuroinflammatory changes, most reported
neurobiological abnormalities in ASD are inconsistent.
Structurally, abnormalities have been described in the cerebel-
lum, hippocampus, amygdala, and insular cortex (32). Abnormal
brain volume has also been identified [for review see Ref. (33)]. A
Table 2 | Behavior and immune functions in ASD [adapted from Ref. (84)].
Studies n Age Assessment method Immune measure Behavior measure
Ashwood et al.
(28)
143 2–5 ADI-R, ADOS, SCQ,
VABS, MSEL, and ABC
Plasma levels of active TGFβ1 Lower TGFβ1 levels were associated with lower adaptive
behaviors and worse behavioral symptoms
Iwata et al.
(89)
37 20–25 ADI-R Plasma levels of P-selectin Lower levels of P-selectin associated with poor social
development
Heuer et al.
(90)
271 2–5 ADI-R, ADOS, and ABC IgG levels in plasma Decreased IgG associated with increased aberrant
behaviors
Grigorenko
et al. (91)
1059 n/s ADI-R and ADOS Genotyping of the MIF gene
and plasma levels of MIF
(n=20)
Plasma MIF levels were positively correlated with worse
scores on ADOS for social impairment and imaginative
skills
Onore et al.
(92)
60 2–5 ADOS, ADI-R, MSEL,
VABS, and ABC
Induced cytokine response to
PHA
Negative correlation between PHA induced IL-23
production and sociability scores of the ADOS
Enstrom et al.
(93)
30 2–5 ADI-R, ADOS, SCQ,
VABS, MSEL, and ABC
Monocyte TLR ligand
stimulation
More impaired social behaviors and non-verbal
communication are associated with increased production
of IL-1β and IL-6 after TLR4 stimulation
Ashwood et al.
(94)
139 2–5 ADI-R, ADOS, SCQ,
VABS, MSEL, and ABC
Induced cytokine response to
PHA and LPS
Pro-inflammatory or TH1 cytokines were associated with
greater impairments in core features of ASD as well as
aberrant behaviors; GM-CSF and TH2 cytokines were
associated with better cognitive and adaptive function
Goines et al.
(95)
466 2–5 ADI-R, ADOS, SCQ,
VABS, MSEL, and ABC
Antibodies directed against a
45 or 62 kDa cerebellum
protein
Children with antibodies directed against a 45-kDa
cerebellum protein had increased lethargy and
stereotypy; children with antibodies against a 62-kDa
cerebellum protein showed increased aberrant behaviors
on the VABS composite standard score
Kajizuka et al.
(96)
62 6–19 ADI-R Serum levels of PDGF Increased serum levels of PDGF-BB homodimers
positively associated with increased restricted, repetitive,
and stereotyped patterns of behavior and interests
Ashwood et al.
(31)
175 2–5 ADI-R, ADOS, SCQ,
VABS, MSEL, and ABC
Plasma chemokines CCL2,
CCL5, and eotaxin
Plasma chemokine levels associated with higher aberrant
behavior scores and more impaired developmental and
adaptive function
Ashwood et al.
(97)
223 2–5 ADI-R, ADOS, SCQ,
VABS, MSEL, and ABC
Plasma levels of cytokines
IL-1β, IL-6, IL-8, and IL-12p40
Elevated cytokine levels in plasma were associated with
more impaired communication and aberrant behaviors
Ross et al. (98) 16 3-31 ADI-R GM-CSF, INFγ, IL-12p70, IL-1β,
IL-6, IL-8, TNFα, and IL-10
Elevation of cytokines correlated with autistic symptoms
in patients with 22q11.2 deletion syndrome
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meta-analysis reported on an average of 13% smaller brain volume
at birth, an average of 10% larger brain volume at 1 year of age than
controls, and 2% larger in adolescence (33). An increase in gray
matter with a reduced unit density has been quite reliably identi-
fied in this cohort (33). CSF volume has also been reported to be
increased with enlarged ventricles (34) and mini-columnar size is
decreased (35). It has been proposed that such structural varia-
tion may affect adaptation and hence learning, and may account
for the heterogeneity and wide-ranging functional deficits seen
in ASD (36). Disordered neural connectivity has been discussed
for some time (37). The evidence supports under-connectivity
between sensory cortices and association cortices in moderate to
severe ASD, essentially leading to a failure to assimilate sensory
information into a working environmental context, and a lack of
connectivity of associative cortices to the frontal cortex in higher
functioning autism (38). This helps explain associated learning
difficulties in low functioning autism, and the poor fine motor
control and impaired imitation identified in higher functioning
autism (39–41).
AUTONOMIC DYSFUNCTION
Autonomic involvement in ASD has been widely reported for over
30 years (42–52). A recent controlled trial explored in detail the
nature and type of autonomic involvement (49). Real-time vari-
ability together with continuous monitoring of blood pressure and
breathing rhythms were assessed in an ASD cohort versus controls.
Over 80% of the ASD cohorts were found to have a reduced vagal
tone, highly suggestive of low central parasympathetic activity and,
significantly, in a separate study, vagal tone in the neonate was
found to predict neurodevelopmental outcome more accurately
than birth weight, socio-economic status, or co-morbid medical
conditions (50). Given that the autonomic nervous system (ANS)
is responsible for the majority of sensory information received by
the central nervous system, any disruption to the ANS is likely to
have wide-ranging effects on higher cortical development. In a lon-
gitudinal follow-up study, Goytag et al. examined the order of cor-
tical development using repeat MRI and concluded: higher-order
association cortices mature only after lower-order somatosensory
and visual cortices, the functions of which they integrate, are devel-
oped (53). The development of a normal parasympathetic tone
is thus likely to be crucial for adequate neurodevelopment [for
review see Ref. (50)]. More research is required.
ENVIRONMENTAL ASPECTS OF ASD
Hertz-Picciotto et al. provide a detailed review of developmental
immunotoxicity (DIT) in relation to neurodevelopment disor-
ders (54). Xenobiotic exposure in early life may lead to altered
immune function throughout life, a persistent neuroinflammatory
response and systemic immune dysregulation, and the possibility
of a neurobehavioral manifestation of the disease (54).
The type of immune dysfunction relates to the type of xeno-
biotic involved and the timing of xenobiotic exposure with dose-
dependent effects not as applicable in the developing immune sys-
tem but specific neurological development depends on signaling
from the immune system (55). Such conveyance of environ-
mental state to the nervous system from the immune system is
advantageous and essential, but is incompatible with adequate
neurodevelopment in poor environmental conditions. Whether
there is a single type of xenobiotic involved in the etiology of ASD
or whether the pathophysiology involves exposure to general envi-
ronmental pollution remains a keenly researched area. Pesticides,
flame retardants, heavy metals, traffic fumes, and endotoxins have
all been implicated (56–61). The apparent lack of consistency is
further compounded by difficulties in measuring chronic toxi-
city and toxin-induced disruption particularly if the xenobiotic
exposure is no longer present.
Dietert et al. describes several similarities between early-life
immune insults (ELII), including DIT and ASD with gender dif-
ferences, time-windows for immune development, and the cor-
responding variable presentation in both ELII and ASD making
a compelling argument (62). Studying DIT and indeed develop-
mental neurotoxicity requires functional measures and a history of
significant exposure. Complicating matters further is the modest,
but significant genomic variation in xenobiotic metabolism and
hence resistance or vulnerability to environmental exposures.
ABNORMALITIES IN GUT MICROFLORA IN ASD
Abnormal clostridia species have been found repeatedly in ASD
(63–67). The theory of clostridia involvement was postulated by
Bolte in 1998 who suggested that clostridia toxin adversely affected
neurotransmitter function that could result in neurobehavioral
changes presenting as autism (68). Supporting this hypothesis,
Parracho et al. outlined robust measures of microflora abnor-
malities in ASD cases suffering from bowel problems using PCR
analysis and found a clear and consistent abnormality in the
clostridia species present in ASD sufferers versus controls.Clostrid-
ium histolytica were found in higher levels in the ASD group versus
healthy unrelated controls (p< 0.01) and healthy related controls
(p< 0.05) (65).
A clinical trial was carried out to assess the bowel and behavioral
impact of anti-microbial therapy directed against these abnormal
clostridia species (69). Oral vancomycin was used for 6 weeks.
Behavioral measurements were carried out before and after, as
well as clinical assessment of bowel symptoms. The numbers were
low but the response to intervention was reported as statistically
significant. 8 of the 10 patients studied improved in terms of
behavior and bowel symptoms with some scoring within the neu-
rotypical range. Discontinuation of vancomycin after the 6-week
trial period led to a gradual regression in bowel and behavioral
symptoms in all participants (69) suggesting that gut environ-
ment gives preference to these abnormal species. As yet, there has
been no investigation of the combined approach of anti-microbial
therapy and other interventions targeted at altering microbiota
composition.
Williams et al. recently reported consistently abnormal Firmi-
cutes to Bacteriodetes ratios from biopsy specimens in children
with ASD versus inflammatory bowel disease (IBD) controls. This
was linked to reduced disaccharidases (starch digesting enzymes),
which in the same study were also found to be low in the ASD
group. Williams et al. postulated a link between high carbohydrate
transit to the large intestine in ASD leading to alteration in the
proportion of Firmicutes to Bacteriodetes. The appearance of this
“compositional dysbiosis” was highly correlated in the ASD group
with Firmicutes to Bacteriodetes ratio of 31:69 (versus controls
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27:73) in the ileal biopsies (p< 0.0006) and 32:68 (versus controls
25:75) in the cecal biopsies (p< 0.022) (66).
Although microflora are known to alter host immune function,
including cytokine production [for review see Ref. (70–73)], to
our knowledge there has, to date, been no investigation of the rela-
tionship between abnormal microflora and cytokine production
in ASD, although a few studies have examined cytokines in ASD
patients with bowel symptoms and found positive correlations
(72–74).
DISCUSSION
It is the wide heterogeneity of ASD that poses the greatest chal-
lenge. Identifying a common pathophysiology is hampered by
such diversity as is the identification of management strategies,
both behavioral and medical. Equally those faced with patient
care often struggle to discern the range of presentations and the
impact this has on management. ASD shares simply, a marked
impairment with any of the faculties required for social integra-
tion; this can present with a lethargic, disinterested child or an
agitated, distracted child or any number of features leading ulti-
mately to impaired social integration. It may be that in order to
determine treatment response, we must first delineate/categorize
treatable groups. Indeed if some form of environmental insult
occurs early on in development (be it infection, toxicant, or other
environmental stressor), then it may not only cause variable man-
ifestations based on timing, nature, and genomic individuality, it
may also leave no discernible or at least easily discernible trace. It
may, as Hertz-Piciotta et al. (54) and Dietert et al. (62) suggest,
merely be an event that primes or disrupts a critical window in
development. Given the wide-ranging heterogeneity of the disor-
der and the many faculties required for social integration, it may be
neither the insulting agent, the timing, the genomic vulnerability
nor the system(s) affected that remain static or, when ASD is taken
as a single consequential expression, statistically identifiable.
Within the developing neurological, immunological, and neu-
roimmunological systems, there is vulnerability to environmental
insult. Depending on the nature, timing, and duration of insult,
neurological, immunological, or neuroimmunological abnormal-
ities may predominate, and the relative proportion each system is
affected will vary accordingly (see Figure 1).
Socialization and speech are complex neurological functions.
ASD may represent impairment in any system/faculty required
to facilitate such complex neurological functions. There is likely
ample opportunity for an environmental insult to disrupt one or
more of the mechanisms leading to the impairment of the higher-
order processes of social integration and along the way disrupt a
number of other physiological mechanisms that may contribute
or indeed cause the additional and variable behavioral manifesta-
tions within the spectrum of disease. As troublesome as the notion
may be, and granted there will be reasonable pathophysiological
correlations identified particularly within sub-groups, the great-
est commonality in ASD may be etiological, and even then it may
merely be a trend in human–environment relationship versus an
exact noxious substance.
Similar hypotheses have been presented by others: e.g., Dietert
et al. (47), Hertz-Picotta et al. (46), Goines and Ashwood (75), and
Unwin et al. (76). The central theme is the presence of a variable
insult leading to the variable presentation of ASD. In recognition
of these previous studies, the hypothesis presented here is referred
to as the variable insult model of ASD. Such hypotheses are criti-
cal to providing a framework to identify sub-types within the ASD
group, building in some predictability both for researchers and
for those faced with clinical management. Such sub-typing can be
based on the dominant system pathophysiology involved or one
can attempt clinical classification. Table 3 is an example of such an
attempt at clinical sub-typing based on the variable insult model
of ASD.
The sub-categories presented in Table 3 are broad and overlap
considerably. More specific sub-typing seems probable, perhaps
relating to the intensity of the insult and perhaps more specifi-
cally to the offending agent, as suggested recently by Unwin et al.
(76). Already abnormal RNA transcription has been identified
in ASD children correlating with environmental toxicants versus
controls with similar levels of toxicants (77, 78). The transcription
abnormalities are specific to the toxicant, raising the possibility of
different etiological agents triggering different initial pathophysio-
logical mechanisms sharing only the secondary consequences. The
factors involved in the different gene expression in ASD, whether
they be linked to genomic individuality, previous exposure, some
kind of immunological priming, or abnormal GI flora, raises inter-
esting questions, but in these current considerations the mere
difference in RNA transcription between different xenobiotics and
also between ASD patients versus control groups raises important
questions about accurate delineation of sub-types and the differ-
ent pathophysiological mechanisms involved in the eventual ASD
outcome.
Variable pathophysiological pathways leading to ASD seem
likely, and recent advancements in scientific techniques carry the
capacity to differentiate each pathway with relevance to the pre-
vention and clinical management of the condition. For example,
PCR analysis of GI microflora continues to reveal deeper insights
into the common GI abnormalities prevalent in ASD (65, 66,
81). Evidence demonstrates the importance of such microflora
on immune and neurological function, and the evolution of
GI microflora composition over the first few years of life (82,
83). The compositional dysbiosis discovered by Williams et al.
(66) in ASD patients may reflect another common manifesta-
tion of ASD due perhaps to similar complexities as is involved
in social integration with genomic, neurological, immunolog-
ical, and neuroimmunological systems required to select and
regulate the GI microflora. This may explain the frequently
reported presence of abnormal species in ASD and the diver-
sity of such abnormal microflora/pathogens [for review see Ref.
(65, 81)]; the selection and regulation processes are also part
of the developmental process and are vulnerable to a variety of
insults at a variety of levels. ASD diagnosis may be more scien-
tifically sound should it move toward a formulation including
environmental exposure, genomic vulnerability, and the identi-
fication of the system(s) pathophysiology with treatment inter-
ventions based on such measurable criteria. Animal models can
serve such ever increasing sub-categorization, modeled to reflect
each category and utilized to identify novel therapeutic interven-
tions at specific groups. Without such an appreciation of the
variability associated with ASD, it may be difficult to achieve
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FIGURE 1 | Cascade of effects originating in neurodevelopmental insults
occurring at different points in development. Insults can occur at any point
in neurodevelopment from embryonic through to juvenile and perhaps even
adulthood. Insults to neural crest and neural tube development in the embryo
would have structural and functional outcomes in all peripheral neural
elements including autonomic (sympathetic, parasympathetic), peripheral
sensory system, and enteric (gut) nervous system. Neural tube effects might
also produce changes in central autonomic functions and/or set points for
physiological control systems resident in the hypothalamus and brain stem
autonomic nuclei. Factors affecting cortical development would have an
impact on higher cortical functions including psychosocial, sensory
processing, and motor functioning. Any of these neurodevelopmental effects
would have cascading effects through the sensory and neuro-immune
pathways to neurological, neuro-immune, and immune functions.
statistical significance in treatment trials targeted at specific
deficits.
The variable insult hypothesis predicts diverse immune-related
abnormalities, probability of poor GI microflora regulation, vari-
able autonomic function with impaired/disordered autonomic
reactivity, and variable neuroanatomical findings. Further, the
variable insult model predicts that ASD animal models could
be established through a variety of mechanisms. Valproate with
an acute single dose administered gestationally at E12.5 leads
to ASD symptomatology in rats (79), as does valproate admin-
istered in a sub-chronic dosing given between post-natal days
P6–12, albeit the sub-chronic dosing may have more sensory
issues (80). Unwin et al. (76) proposed that homogeneity may
be found by identifying the etiological agent, and presents the
differences in associative symptomatology in children with ASD
who had either perinatal exposure to selective serotonin re-uptake
inhibitor (SSRI) or who had low birth weight (LBW). The SSRI
group seemed to have more gastrointestinal disturbance, although
it was not clear whether this was a depression effect or drug effect,
and the LBW group had more sleep and breathing disturbance.
Within the variable insult model of ASD, SSRI exposure may
represent greater disruption to the peripheral ANS, perhaps dur-
ing neural crest formation and development, whereas the LBW
group may have suffered more pronounced central autonomic
disruption. Difficulties with sensory processing may then affect
both groups through different mechanisms with similar social
outcomes.
If we start to look at the etiological agents contributing to the
development of ASD, then perhaps we can start to find sub-groups.
Such an approach brings more complexity to the clinical assess-
ment of patients suffering from ASD but perhaps such a complex
condition requires greater effort and more complex formulations
prior to predicting prognosis and response to medical or behav-
ioral management. If we go further still and delineate the various
pathophysiologies that can lead to ASD symptomatology through
animal and human experiments, then early identification of the
system(s) requiring attention may be possible and may then better
guide harm reduction strategies. Prevention remains the prior-
ity, but harm reduction through focused scientific investigation
could reduce the burden of disease going forward. For example,
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Table 3 | Broad clinical sub-categories of ASD.
Prenatal –
birth
Infant – early child
(birth to 3 years)
Early
acute
insult
Early
chronic
insult
Late
acute
insult
Late
chronic
insult
Congenital abnormalities ++++ +++ + +
Severe dysmotility ++++ +++ ++ ++
Sudden regression + ++ ++++ +++
Insidious regression ++ +++ + ++++
Early immune-related issues +++ ++++ ++ ++
Motor delays ++++ +++ + +
Family history of autoimmunity ++ ++ ++++ +++
Gestational exposure ++++ +++ + +
Early infancy exposure + ++ ++++ ++++
The number of crosses indicates the severity/frequency of each measure rela-
tive to age of exposure and its duration. Early acute insult refers to a sudden
or relatively sudden, usually marked exposure to xenobiotic, infection, or other
environmental stressor during prenatal or gestational periods. Early chronic insult
refers to a sustained usually moderate level of exposure over a period of months
during prenatal and/or gestational period. Late acute insult refers to a sudden
or relatively sudden, usually marked exposure to xenobiotic, infection, or other
environmental stressor in infancy to early childhood (birth to 3 years). Late chronic
insult refers to a sustained moderate level of exposure over a period of months
during infancy to early childhood.
in Unwin et al.’s SSRI group, early intervention relating to GI
pathology could allow correction of the dysfunctional peripheral
autonomic input and thus permit greater sensory integration, and
thus improved developmental outcome. Equally addressing the
breathing dysrhythmias in the LBW group may improve auto-
nomic reactivity improving both sensory integration and neuro-
immune responsiveness. Elsewhere, we present clinical data to
support such a possibility through improved autonomic function
following management of co-morbid health conditions and the
subsequent improvement in ASD symptoms.
CLINICAL APPLICATION
The pathophysiology of ASD remains largely unknown. Evidence
so far suggests prognosis is not pre-determined and there is a
dynamic component of the disease. The greater frequency of extra-
CNS disease(s) (85–88), increased respiratory and GI-related
childhood mortality, and substantially greater risk of progressive
seizure disorders (20–22) together with the frequently reported
neuroinflammatory changes (2–5) in ASD suggests ongoing dis-
ease activity, and whilst targeted treatment trials are awaited these
tangible aspects of disease must be the focus of clinical interven-
tion. Actively seeking extra-CNS disease in ASD and pro-actively
managing such conditions, with the appreciation that presentation
of such disease and response to intervention may not be typical
or, whilst the pathophysiology remains ill-defined, predictable, is
a pillar of harm reduction. Delineating sub-groups further will
hopefully help predict the areas requiring further attention in each
patient group.
SUMMARY
Autism spectrum disorder is a severe neurological condition with
variable presentation, disease evolution, and variable, albeit gen-
erally poor, functional outcomes. Patients with ASD have greater
risk of physical and mental health complications, and also a greater
mortality. Neuroinflammation, peripheral immune abnormali-
ties, and environmental factors have consistently been identified,
further supporting the need for research that prioritizes disease
prevention and harm reduction. The results from large epidemi-
ological studies are awaited to identify potential key areas for this
research.
Heterogeneity has been a significant barrier to successful inter-
vention in ASD. It may be that the commonality of impaired social
integration represents dysfunction of a wide variety of systems and
faculties during a crucial developmental period required for the
complexities of social integration and as such the commonality
is merely etiological. Similar levels of intricacy may explain the
propensity to abnormal acquisition of GI flora during an equally
important microbiota developmental period. Here, we reviewed
the most promising research findings to explain the diverse neuro-
logical, immunological, and neuroimmunological abnormalities
in ASD within consideration of variable environmental insults.
In our opinion, this provides a useful framework to under-
stand and further explore this devastating neurodevelopmental
condition.
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